Outlook Therapeutics
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab ...
Outlook Therapeutics Logo
About Outlook Therapeutics
Outlook Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The Company engages in identifying, developing, manufacturing, and commercializing complex biosimilar therapeutics, as well as focuses on monoclonal antibodies in the disease areas of immunology and oncology aspects. Outlook Therapeutics serves clients in the United States.
Address
111 S. Wood Avenue, Unit #100
Iselin, 08830
United States
Year founded
2015
Number of employees
0-100
Report inaccurate data
Request an update to help us keep the brand up-to-date.
